The surge in ads for weight-loss drugs Ozempic and Wegovy on Facebook and Instagram raises questions about Meta Inc.'s enforcement of its advertising policy. This could lead to negative sentiment towards the company and potentially impact its stock price in the short term. The issue also highlights the broader concerns about the role of social media platforms in promoting body image issues and eating disorders.